Biocryst Pharmaceuticals Stock News

Wall Street analysts predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report $46.56 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for BioCryst Pharmaceuticals earnings, with estimates ranging from $42.00 million to $50.88 million. BioCryst Pharmaceuticals posted sales of $4.02 million in the same quarter last []

Wall Street analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings of ($0.32) per share for the current quarter, Zacks reports. Four analysts have issued estimates for BioCryst Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.38). BioCryst Pharmaceuticals posted earnings of ($0.34) per share []

Related Stocks: EPZM , MRUS , ADCT , YMAB , MEIP , NTLA , BCRX , CYTK , VSTM , GERN ,

Related Stocks: ^BFX , BCRX , NTLA , EPZM , EPIX , NEO , MEIP ,

Wall Street brokerages predict that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will announce ($0.32) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioCryst Pharmaceuticals earnings, with estimates ranging from ($0.38) to ($0.27). BioCryst Pharmaceuticals posted earnings of ($0.34) per share during the same quarter last year, []

Millennium Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1,687.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 715,140 shares of the biotechnology companys stock after buying an additional 675,140 shares during the period. Millennium []

Here are seven top growth stocks investors may want to consider when looking at options in this hyper-growth market right now. The post 7 Top Growth Stocks to Buy as We Step Into November appeared fir

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q3 2021 Results - Earnings Call Transcript

The biotech's third quarter was a good one, once you look past the top-line numbers.

RESEARCH TRIANGLE PARK, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts, including one Distinguished

RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on

These growth stocks could become multi-baggers in the future. Investors should consider them as they start to move at an aggressive pace.

These two small drugmakers are poised for a long-winded growth spurt.

RESEARCH TRIANGLE PARK, N.C., Oct. 04, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.